



152 Page

152

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicant: Oppermann et al.

Examiner:

FEB 14 1991

Serial No.: 621,988

Group Art Unit: GROUP 150

Filed: December 4, 1990

Attorney Docket: CRP-0012DV

Title: OSTEOGENIC PROTEINS

S. Prior Art

Honorable Commissioner of Patents and Trademarks
Washington, DC 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Honorable Commissioner of Patents and Trademarks, Washington, DC 20231 on the date set forth below.

02/06/91
Date of Signature
and of Mail Deposit

By [Signature]
Robin D. Kelley
Registration No. P-34,637

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their attorney are aware of the following publications and information, and in accordance with 37 CFR 1.97, hereby make a record of those publications which have been identified in, or reviewed during the preparation of this application. The pertinence of each publication listed as presently understood is described below.

152
1/22/91
000

173

All of the documents described herein have been submitted for the parent case from which this case depends (USSN 315,342, filed February 23, 1989), as well as for previously filed related cases (see for example, USSN 232,630, filed April 15, 1988 and U.S Patent No. 4,968,950) and have been duly recorded by the Examiner in each case. Accordingly, with the Examiner's permission (granted in a telephone conversation with Examiner Nutter on September 25, 1990), copies of these documents are not enclosed as they previously have been provided and now are of record.

U.S. 4,294,753 is understood to relate to the process of separating bone morphogenetic protein from demineralized bone tissue.

U.S. 4,394,370 is understood to relate to an osteogenic collagen conjugate material, particularly in the form of a sponge, and to a process for making this material. The material is comprised primarily of reconstituted collagen.

U.S. 4,434,094 is understood to relate to partially purified osteogenic factor and to a process for preparing it from demineralized bone.

U.S. 4,455,256 is understood to relate to the characterization of bone morphogenic protein prepared from demineralized bone.

174

U.S. 4,563,350 is understood to disclose a composition suitable for inductive bone implants comprising a carrier having a percentage of non-fibrillar collagen.

U.S. 4,563,489 understood to relate to a polylactic acid polymer delivery system for bone morphogenic protein.

U.S. 4,877,864 is understood to claim an amino acid sequence isolated from bone (BMP-1) and a DNA sequence encoding it. This protein is purported to have osteogenic activity.

PCT/US89/09605 is understood to disclose a polypeptide sequence isolated from bone having osteogenic activity at non-bony sites in the presence of TGF- β .

PCT/WO85/05274 is understood to disclose a collagenous fibrous tissue preparation for repair of cutaneous wounds and soft tissue injuries. The tissue preparation, preferably in sheet form, is produced by treatment of the tissue with a polyisocyanate.

PCT/WO86/00526 is understood to claim a method for treating implants to enhance or stimulate cartilage and/or bone formation.

175

PCT/WO88/00205 is understood to relate to the partial purification of bovine bone morphogenic factors from bone and to the identification of genetic sequences using probes derived from tryptic digests of the impure factor mix.

PCT/WO89/10409 is understood to disclose a polypeptide sequence isolated from bone (BMP-3), and a DNA sequence encoding it. The protein is purported to have osteogenic activity.

PCT/WO90/03733 is understood to describe the isolation and analysis of a family of osteogenic factors called "P3 OF 31-34." This protein family contains at least four proteins, which are characterized by peptide fragment sequences. Only the impure mixture P3 OF 31-34 is assayed for osteogenic activity.

EPO 128,041 is understood to describe three polypeptide compositions exhibiting skeletal growth factor activity.

EPO 148,155 is understood to relate to a protein extracted from demineralized bone reportedly capable of promoting osteogenesis, and to a method for its isolation and purification. The matrix used in bone growth assays is prepared by conventional methods.

176

EPO 169,016 is understood to disclose two polypeptide cofactors isolated from bone having chondrogenic and TGF- β activity.

EPO 182,483 is understood to claim a composition suitable for inductive bone implants comprising non-fibrillar, atelopeptide collagen.

EPO 212,474 is understood to relate to the production and isolation of bone morphogenic peptide agents by recombinant means. The matrix used in bone growth assays is prepared by conventional methods.

Canalis et al. (1980) is understood to relate to the stimulation of DNA and collagen synthesis by a growth factor in cultured fetal rat calvariae.

Glowacki et al. (1981) is understood to relate to the application of demineralized bone implants for cranio-maxillofacial reconstruction involving osteogenesis.

Reddi (1981) is understood to relate to a review of the cell biology and biochemistry of endochondral bone development, including a discussion of the developmental cascade of bone resorption and remodeling.

177

Sampath et al. (1981) is understood to relate to the dissociative extraction and reconstitution of extracellular matrix components involved in local bone differentiation.

Farley et al. (1982) is understood to relate to human skeletal growth factor and to characterization of its mutogenic effect on bone cells in vitro.

Maugh (1982) is understood to announce the isolation of human skeletal growth factor and distinguishes it from bone morphogenic protein.

Sampath et al. (1983) is understood to relate to the bone inductive proteins from human, monkey, bovine, and rat extracellular matrix, and to a comparison of their biochemical and enzymatic characteristics.

Seyedin et al. (1983) is understood to describe an in vitro system developed to study the onset of chondrogenesis.

Urist et al. (1983) is understood to relate to the physical and biological characterization of several human bone morphogenetic proteins extracted from demineralized, gelatinized cortical bone matrix.

174

Simpson (1984) is understood to review the role of growth factors in both bone resorption and formation, as understood to date.

Urist et al. (1984) is understood to relate to the differentiation of cartilage into bone by induction with an aggregate of β -tricalcium phosphate and bone morphogenetic protein.

Urist et al., II (1984) is understood to relate to the purification and characterization of several bovine bone morphogenetic proteins by hydroxyapatite chromatography.

Centrella et al. (1985) is understood to relate to the purification and characterization of transforming and nontransforming growth factors present in medium conditioned by fetal rat calvariae.

Klausner (1985) is understood to relate to the isolation of two cartilage-inducing factors, and to an in vitro assay for chondrogenetic activity.

Olson et al. (1985) is understood to describe the deglycosylation of chondroitin sulfate proteoglycan with hydrogen fluoride in pyridine.

179

Reddi (1985) is understood to relate to the cascade of implant-stimulated interface reactions which occur during collagenous bone matrix-induced bone formation.

Sampath et al. (1985) is understood to relate to a review of the cellular and biochemical events associated with matrix-induced endochondral bone formation, and to the role of extracellular matrix components in these events.

Seyedin et al. (1985) is understood to relate to the purification of two cartilage-inducing factors from bovine demineralized bone including dissociative extraction, gel filtration, cation exchange chromatography, and reverse phase HPLC. It also is understood to relate to the characterization of these cartilage-inducing factors.

Colowick et al. (1987) is understood to describe a method of preparing bone morphogenic protein and polypeptide fragments.

Padgett et al. (1987) is understood to disclose the cDNA sequence of a drosophila development gene (DPP-C) and indicates its homology to the related genes of the TGF- β gene family.

140

Sampath et al. (1987) is understood to relate to the isolation and characterization of an extracellular, matrix-associated bone inductive protein by heparin affinity chromatography.

Weeks et al. (1987) is understood to relate to the characterization and localization of a maternal mRNA from *Xenopus* eggs which encodes a member of the transforming growth factor-B family of proteins (Vg-1).

LeGendre et al. (1988) is understood to relate to the use of Immobilon transfer membranes on to which proteins have been electrophoretically transferred for direct protein sequencing in a gas phase sequencer.

Wang et al. (1988) is understood to relate to the isolation and characterization of factors from bovine bone that induce cartilage and ectopic bone formation in vivo.

Wang et al., II (1988) is understood to relate to the isolation and characterization of factors from demineralized bone that induce cartilage and new bone formation in vivo.

Wozney et al. (1988) is understood to relate to the cloning and identification of three proteins involved in in vivo cartilage formation.

181


Wozney et al., II (1988) is understood to relate to the cloning and identification of three proteins involved in in vivo cartilage formation.

Lyons et al. (1989) is understood to relate to a sequence comparison of Vgr-1 DNA with that of other DNA sequences corresponding to proteins thought to be in the TGF- β superfamily.

Wang et al. (1990) is understood to describe the expression and partial purification of one of the cDNA sequences described in W088/00205. Consistent cartilage and/or bone formation with this composition requires 600 ng of 50% pure material.

Respectfully submitted,

LAHIVE & COCKFIELD


Robin D. Kelley
Reg. No. P-34,637

60 State Street
Boston, MA 02109
(617) 227-7400
Date: February 6, 1991

148